aspirin has been researched along with Diabetic Nephropathies in 45 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40) were randomly assigned to sarpogrelate (300 mg/d; n = 20) or aspirin group (100 mg/d; n = 20)." | 9.13 | Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008) |
| "There was no significant difference in urinary proteinuria after 6 weeks of treatment with placebo or celecoxib (proteinuria ratio, celecoxib versus placebo, 1." | 9.12 | A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. ( Chen, H; Clyne, S; Han, E; Harris, R; Lehrich, R; Lewis, J; Middleton, J; Rodby, R; Schulman, G; Shyr, Y; Sika, M; Sinsakul, M, 2007) |
| "To define the importance of renal prostaglandins in nephrogenic diabetes insipidus (NDI), diuresis and the urinary excretion of PGE2 and PGF2 alpha were studied in a patient with NDI before and during inhibition of endogenous prostaglandin synthesis with either indomethacin (IND) or acetyl-salicylic acid (ASA)." | 7.67 | Comparative therapeutic benefit of indomethacin, hydrochlorothiazide, and acetyl-salicylic acid in a patient with nephrogenic diabetes insipidus. ( Favre, L; Jörg, J; Vallotton, MB; Vierhapper, H; Waldhäusl, W, 1984) |
| "The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial was a prospective, randomized, open-label trial conducted throughout Japan that enrolled 2,539 type 2 diabetic patients without a history of atherosclerotic diseases." | 5.15 | Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. ( Akai, Y; Doi, N; Jinnouchi, H; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Soejima, H; Sugiyama, S; Uemura, S; Waki, M, 2011) |
| "Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40) were randomly assigned to sarpogrelate (300 mg/d; n = 20) or aspirin group (100 mg/d; n = 20)." | 5.13 | Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008) |
| "There was no significant difference in urinary proteinuria after 6 weeks of treatment with placebo or celecoxib (proteinuria ratio, celecoxib versus placebo, 1." | 5.12 | A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. ( Chen, H; Clyne, S; Han, E; Harris, R; Lehrich, R; Lewis, J; Middleton, J; Rodby, R; Schulman, G; Shyr, Y; Sika, M; Sinsakul, M, 2007) |
| "During a 1-year treatment period, simvastatin, 20 mg/d, produced a sustained reduction of approximately one quarter in low-density lipoprotein cholesterol levels, with no evidence of toxicity, and aspirin, 100 mg/d, did not substantially increase the risk for a major bleeding episode." | 5.11 | First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. ( Altmann, P; Armitage, J; Baigent, C; Baxter, A; Cairns, HS; Collins, R; Foley, RN; Frighi, V; Kourellias, K; Landray, M; Leaper, C; Ratcliffe, PJ; Rogerson, M; Scoble, JE; Tomson, CR; Warwick, G; Wheeler, DC, 2005) |
| "Aspirin is recommended as cardiovascular disease prevention in patients with diabetes mellitus." | 4.84 | [Low-dose aspirin in patients with diabete melitus: risks and benefits regarding macro and microvascular complications]. ( Camargo, EG; Gross, JL; Lavinsky, J; Silveiro, SP; Weinert, LS, 2007) |
| " Increased leptin, dysregulation of adipocyte proteins, increased insulin resistance and C-reactive protein may be factors involved in the increased incidence of cardiovascular morbidity and mortality directly related to obesity." | 4.83 | Stroke prevention in diabetes and obesity. ( Govindarajan, G; Kurukulasuriya, LR; Sowers, J, 2006) |
| "Aspirin administration, reduced the protein expression of Mysm1, increased the protein expression of H2AK119-Ub and thereby reduced the Set7 protein expression in glomeruli isolated from diabetic animals and prevented renal fibrosis." | 3.88 | Novel reno-protective mechanism of Aspirin involves H2AK119 monoubiquitination and Set7 in preventing type 1 diabetic nephropathy. ( Gaikwad, AB; Goru, SK, 2018) |
| " This adherence was concerned particularly with co-medication in patients diagnosed with hypertension, aspirin prescription in elderly patients and the achievement of target lipid levels following the prescription of statins." | 3.79 | Sex-specific-differences in cardiometabolic risk in type 1 diabetes: a cross-sectional study. ( Hintersteiner, J; Johnson, J; Kamyar, MR; Kautzky, A; Kautzky-Willer, A; Lemmens-Gruber, R; Saukel, J; Stich, K, 2013) |
| "We sought to assess the impact of renal function on platelet reactivity in patients with diabetes mellitus (DM) and coronary artery disease on aspirin and clopidogrel therapy." | 3.76 | Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. ( Alfonso, F; Angiolillo, DJ; Bass, TA; Bernardo, E; Capodanno, D; Fernandez-Ortiz, A; Ferreiro, JL; Jimenez-Quevedo, P; Macaya, C; Sabaté, M; Ueno, M; Vivas, D, 2010) |
| "To define the importance of renal prostaglandins in nephrogenic diabetes insipidus (NDI), diuresis and the urinary excretion of PGE2 and PGF2 alpha were studied in a patient with NDI before and during inhibition of endogenous prostaglandin synthesis with either indomethacin (IND) or acetyl-salicylic acid (ASA)." | 3.67 | Comparative therapeutic benefit of indomethacin, hydrochlorothiazide, and acetyl-salicylic acid in a patient with nephrogenic diabetes insipidus. ( Favre, L; Jörg, J; Vallotton, MB; Vierhapper, H; Waldhäusl, W, 1984) |
| "Seventy-six patients with type-2 diabetic nephropathy, who had normal renal function tests were randomized into the 4 groups; each group (n = 19) received one of the following treatments: aspirin (1000 mg), dipyridamole (750 mg), their combination or placebo daily for 2 months." | 2.70 | A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. ( Khajehdehi, P; Mostafavi, H; Roozbeh, J, 2002) |
| "Subjects with NIDDM were administered either aspirin (100 mg/day) or a combination of basic amino acids consisting of L-arginine (2 g/day) plus L-lysine (0." | 2.68 | Effects of aspirin or basic amino acids on collagen cross-links and complications in NIDDM. ( Blanco, MC; Camejo, M; Contreras, I; Giansante, E; Gonzalez, F; Lopez, T; Martinez, N; Molina, M; Postalian, S; Reiser, KM; Sanchez, MR; Suarez, N, 1997) |
| "Treatment with aspirin-dipyridamole was without effect." | 2.66 | Renal scintigraphy and survival of indium-111-labelled platelets in patients with diabetic nephropathy. ( Barker, MJ; Davies, JA; Hooper, AH; Spencer, AA; Stainton, C; Tindall, H, 1986) |
| "With an increasing incidence, diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease and end-stage renal disease, and conventional therapies did not change this situation." | 2.52 | Antioxidant and antithrombotic therapies for diabetic kidney disease. ( Shen, Y; Xu, G; Yan, W; Zhou, B, 2015) |
| "Careful counseling of women with diabetic nephropathy before pregnancy with estimation of the risk for the mother and fetus is important." | 2.48 | Obstetric nephrology: pregnancy in women with diabetic nephropathy--the role of antihypertensive treatment. ( Clausen, P; Damm, P; Feldt-Rasmussen, B; Mathiesen, ER; Ringholm, L, 2012) |
| "Therefore, prevention and treatment of diabetic nephropathy has become a prominent goal in the treatment of patients with diabetes mellitus." | 2.42 | Prevention and treatment of diabetic nephropathy in older patients. ( Jungmann, E, 2003) |
| "Management of hypertension in diabetic nephropathy is challenging and generally requires a minimum of three different and complementary antihypertensive agents to achieve the recently recommended blood pressure (BP) goal of <130/80 mm Hg in order to reduce cardiovascular (CV) risk and preserve kidney function." | 2.42 | Diabetes and chronic kidney disease: tragedy and challenge. ( Bakris, GL; Chua, DY, 2004) |
| "The best treatment for coronary artery disease (CAD) in patients with type 2 diabetes (DM2) and chronic kidney disease is unknown." | 1.62 | Effect of diabetic kidney disease on therapeutic strategies for coronary artery disease: ten year follow-up. ( Batista, DV; Filho, JPPL; Filho, RK; Garcia, RMR; Garzillo, CL; Hueb, W; Junior, CVS; Lima, EG; Martins, EB; Ramires, JAF; Rezende, PC, 2021) |
| "Inflammation is increasingly seen as the core process in the development of diabetes." | 1.36 | Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy. ( Gaikwad, AB; Mulay, SR; Tikoo, K, 2010) |
| "Aspirin was used in 64% of patients with CAD and in 28." | 1.35 | Control of cardiovascular risk factors and use of aspirin in diabetic patients remain elusive. ( Garg, P; Jeevanantham, V; Khan, A; Nautiyal, A; Reddy, PC; Shrivastava, R, 2008) |
| "To explore its involvement in early diabetic nephropathy, we investigated the time course of CTGF gene expression and its regulation in streptozotocin (STZ)-induced diabetic rat kidney." | 1.32 | Roles of connective tissue growth factor and prostanoids in early streptozotocin-induced diabetic rat kidney: the effect of aspirin treatment. ( Fujinaga, Y; Makino, H; Mori, K; Mukoyama, M; Nakao, K; Suganami, T; Sugawara, A; Tanaka, I; Yahata, K; Yokoi, H, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (22.22) | 18.7374 |
| 1990's | 6 (13.33) | 18.2507 |
| 2000's | 14 (31.11) | 29.6817 |
| 2010's | 13 (28.89) | 24.3611 |
| 2020's | 2 (4.44) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, Z | 4 |
| Li, D | 2 |
| Tian, D | 2 |
| Liu, X | 2 |
| Batista, DV | 1 |
| Hueb, W | 1 |
| Lima, EG | 1 |
| Rezende, PC | 1 |
| Garzillo, CL | 1 |
| Garcia, RMR | 1 |
| Filho, JPPL | 1 |
| Martins, EB | 1 |
| Junior, CVS | 1 |
| Ramires, JAF | 1 |
| Filho, RK | 1 |
| Goru, SK | 1 |
| Gaikwad, AB | 2 |
| Daimon, S | 1 |
| Zhang, Y | 1 |
| Ma, KL | 1 |
| Gong, YX | 1 |
| Wang, GH | 1 |
| Hu, ZB | 1 |
| Liu, L | 1 |
| Lu, J | 1 |
| Chen, PP | 1 |
| Lu, CC | 1 |
| Ruan, XZ | 1 |
| Liu, BC | 1 |
| Kautzky-Willer, A | 1 |
| Stich, K | 1 |
| Hintersteiner, J | 1 |
| Kautzky, A | 1 |
| Kamyar, MR | 1 |
| Saukel, J | 1 |
| Johnson, J | 1 |
| Lemmens-Gruber, R | 1 |
| Sasso, FC | 1 |
| Marfella, R | 1 |
| Pagano, A | 1 |
| Porta, G | 1 |
| Signoriello, G | 1 |
| Lascar, N | 1 |
| Minutolo, R | 1 |
| Carbonara, O | 1 |
| Persico, M | 1 |
| Piscione, F | 1 |
| De Nicola, L | 1 |
| Torella, R | 1 |
| Paolisso, G | 1 |
| Yan, W | 1 |
| Zhou, B | 1 |
| Shen, Y | 1 |
| Xu, G | 1 |
| Dasgupta, A | 1 |
| Steinhubl, SR | 1 |
| Bhatt, DL | 1 |
| Berger, PB | 1 |
| Shao, M | 1 |
| Mak, KH | 1 |
| Fox, KA | 1 |
| Montalescot, G | 1 |
| Weber, MA | 1 |
| Haffner, SM | 1 |
| Dimas, AP | 1 |
| Steg, PG | 1 |
| Topol, EJ | 1 |
| Mulay, SR | 1 |
| Tikoo, K | 1 |
| Angiolillo, DJ | 1 |
| Bernardo, E | 1 |
| Capodanno, D | 1 |
| Vivas, D | 1 |
| Sabaté, M | 1 |
| Ferreiro, JL | 1 |
| Ueno, M | 1 |
| Jimenez-Quevedo, P | 1 |
| Alfonso, F | 1 |
| Bass, TA | 1 |
| Macaya, C | 1 |
| Fernandez-Ortiz, A | 1 |
| Kumar Bhatt, L | 1 |
| Addepalli, V | 1 |
| Saito, Y | 1 |
| Morimoto, T | 1 |
| Ogawa, H | 1 |
| Nakayama, M | 1 |
| Uemura, S | 1 |
| Doi, N | 1 |
| Jinnouchi, H | 1 |
| Waki, M | 1 |
| Soejima, H | 1 |
| Sugiyama, S | 1 |
| Okada, S | 1 |
| Akai, Y | 1 |
| Mathiesen, ER | 1 |
| Ringholm, L | 1 |
| Feldt-Rasmussen, B | 1 |
| Clausen, P | 1 |
| Damm, P | 1 |
| Ward, DR | 1 |
| Novak, E | 1 |
| Scott-Douglas, N | 1 |
| Brar, S | 1 |
| White, M | 1 |
| Hemmelgarn, BR | 1 |
| Jungmann, E | 1 |
| Makino, H | 2 |
| Mukoyama, M | 2 |
| Sugawara, A | 2 |
| Mori, K | 2 |
| Suganami, T | 2 |
| Yahata, K | 2 |
| Fujinaga, Y | 1 |
| Yokoi, H | 1 |
| Tanaka, I | 2 |
| Nakao, K | 2 |
| Chua, DY | 1 |
| Bakris, GL | 1 |
| Baigent, C | 1 |
| Landray, M | 1 |
| Leaper, C | 1 |
| Altmann, P | 1 |
| Armitage, J | 1 |
| Baxter, A | 1 |
| Cairns, HS | 1 |
| Collins, R | 1 |
| Foley, RN | 1 |
| Frighi, V | 1 |
| Kourellias, K | 1 |
| Ratcliffe, PJ | 1 |
| Rogerson, M | 1 |
| Scoble, JE | 1 |
| Tomson, CR | 1 |
| Warwick, G | 1 |
| Wheeler, DC | 1 |
| Kurukulasuriya, LR | 1 |
| Govindarajan, G | 1 |
| Sowers, J | 1 |
| Camargo, EG | 1 |
| Gross, JL | 1 |
| Weinert, LS | 1 |
| Lavinsky, J | 1 |
| Silveiro, SP | 1 |
| Sinsakul, M | 1 |
| Sika, M | 1 |
| Rodby, R | 1 |
| Middleton, J | 1 |
| Shyr, Y | 1 |
| Chen, H | 1 |
| Han, E | 1 |
| Lehrich, R | 1 |
| Clyne, S | 1 |
| Schulman, G | 1 |
| Harris, R | 1 |
| Lewis, J | 1 |
| Thomas, MC | 1 |
| Ogawa, S | 1 |
| Mori, T | 1 |
| Nako, K | 1 |
| Ishizuka, T | 1 |
| Ito, S | 1 |
| Shrivastava, R | 1 |
| Khan, A | 1 |
| Jeevanantham, V | 1 |
| Nautiyal, A | 1 |
| Garg, P | 1 |
| Reddy, PC | 1 |
| Vierhapper, H | 1 |
| Jörg, J | 1 |
| Favre, L | 1 |
| Vallotton, MB | 1 |
| Waldhäusl, W | 1 |
| Patrono, C | 1 |
| Daví, G | 1 |
| De Cosmo, S | 1 |
| Earle, K | 1 |
| Morocutti, A | 1 |
| Walker, J | 1 |
| Ruggenenti, P | 1 |
| Remuzzi, G | 1 |
| Viberti, GC | 1 |
| Homberg, M | 1 |
| Tschöpe, D | 1 |
| Greber, H | 1 |
| Hackländer, T | 1 |
| Schwippert, B | 1 |
| Gries, FA | 1 |
| Mödder, U | 1 |
| Contreras, I | 1 |
| Reiser, KM | 1 |
| Martinez, N | 1 |
| Giansante, E | 1 |
| Lopez, T | 1 |
| Suarez, N | 1 |
| Postalian, S | 1 |
| Molina, M | 1 |
| Gonzalez, F | 1 |
| Sanchez, MR | 1 |
| Camejo, M | 1 |
| Blanco, MC | 1 |
| Adamec, M | 1 |
| Saudek, F | 1 |
| Foggensteiner, L | 1 |
| Mulroy, S | 1 |
| Firth, J | 1 |
| Khajehdehi, P | 1 |
| Roozbeh, J | 1 |
| Mostafavi, H | 1 |
| Muro, S | 1 |
| Ishibashi, R | 1 |
| Ohuchida, S | 1 |
| Maruyama, T | 1 |
| Narumiya, S | 1 |
| Colwell, JA | 2 |
| Halushka, PV | 1 |
| Sarji, K | 1 |
| Levine, J | 1 |
| Sagel, J | 1 |
| Nair, RM | 1 |
| Gordge, MP | 1 |
| Rylance, PB | 1 |
| Neild, GH | 1 |
| Hopper, AH | 1 |
| Tindall, H | 2 |
| Davies, JA | 2 |
| Ehrich, JH | 1 |
| Wurster, U | 1 |
| Lütge, M | 1 |
| Doehring, E | 1 |
| Oemar, B | 1 |
| Nath, KA | 1 |
| Donadio, JV | 1 |
| Ilstrup, DM | 1 |
| Holley, KE | 1 |
| Romero, JC | 1 |
| Moel, DI | 1 |
| Safirstein, RL | 1 |
| McEvoy, RC | 1 |
| Hsueh, W | 1 |
| Hooper, AH | 1 |
| Barker, MJ | 1 |
| Spencer, AA | 1 |
| Stainton, C | 1 |
| George, CR | 1 |
| Slichter, SJ | 1 |
| Quadracci, LJ | 1 |
| Striker, GE | 1 |
| Harker, LA | 1 |
| Kwaan, HC | 1 |
| Cruz, S | 1 |
| Suwanwela, N | 1 |
| Dobbie, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease[NCT03150667] | Phase 4 | 220 participants (Anticipated) | Interventional | 2017-04-10 | Recruiting | ||
| Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel[NCT01328470] | Phase 4 | 85 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial[NCT00110448] | Phase 4 | 2,539 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial[NCT00125593] | Phase 4 | 9,438 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| [NCT00065559] | 30 participants | Interventional | 2003-04-30 | Terminated | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Revascularization included any arterial revascularization procedure, whether surgical or percutaneous, but excluded revascularization performed for hemodialysis vascular access (e.g. fistuloplasty) or to the donor kidney transplant artery. Revascularization included amputations for vascular disease (rather than for trauma or infection). All potential revascularization events (including angiography) were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 284 |
| Placebo | 352 |
End-stage renal disease was defined as initiation of maintenance dialysis or renal transplantation. Temporary dialysis was excluded. All potential dialysis and transplant events were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 1057 |
| Placebo | 1084 |
Major atherosclerotic events defined as non-fatal myocardial infarction or coronary death, non-hemorrhagic stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 526 |
| Placebo | 619 |
Major coronary events defined as coronary death or non-fatal myocardial infarction. Myocardial infarction adjudicated based on the presence of serial changes in cardiac biomarkers (e.g. troponin, creatine kinase), typical ECG changes and typical cardiac symptoms. If myocardial infarction was fatal and post-mortem examination findings were available, this information was also assessed. All potential coronary events were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 213 |
| Placebo | 230 |
Major vascular events defined as non-fatal myocardial infarction or cardiac death, any stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 701 |
| Placebo | 814 |
Major vascular events defined as non-fatal myocardial infarction or cardiac death, any stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 639 |
| Placebo | 749 |
Stroke was defined as rapid onset of focal or global neurological deficit, with duration greater than 24 hours. Clinical notes and brain imaging were sought to determine the stroke etiology, and if the stroke was fatal and post-mortem examination findings were available, this information was also assessed. All potential stroke events (including transient ischemic attack and intracerebral hemorrhage) were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 131 |
| Placebo | 174 |
9 reviews available for aspirin and Diabetic Nephropathies
| Article | Year |
|---|---|
Antioxidant and antithrombotic therapies for diabetic kidney disease.
Topics: Antioxidants; Aspirin; Diabetic Nephropathies; Endopeptidases; Fibrinolytic Agents; Glycated Hemoglo | 2015 |
Obstetric nephrology: pregnancy in women with diabetic nephropathy--the role of antihypertensive treatment.
Topics: Albuminuria; Antihypertensive Agents; Aspirin; Counseling; Diabetes Mellitus, Type 1; Diabetes Melli | 2012 |
Prevention and treatment of diabetic nephropathy in older patients.
Topics: Aged; Albuminuria; Antihypertensive Agents; Aspirin; Blood Glucose; Clinical Trials as Topic; Diabet | 2003 |
Diabetes and chronic kidney disease: tragedy and challenge.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Blood Glucose; Calcium Channel Blocke | 2004 |
Stroke prevention in diabetes and obesity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Blood Glucose; Cardiovascular | 2006 |
[Low-dose aspirin in patients with diabete melitus: risks and benefits regarding macro and microvascular complications].
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Angiopathies | 2007 |
Antiplatelet agents in the prevention of diabetic vascular complications.
Topics: Aspirin; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopathy; Hum | 1993 |
Management of diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Diabetic Nephropathies; | 2001 |
Platelets, antiplatelet therapy, and diabetic nephropathy.
Topics: Aspirin; Diabetic Nephropathies; Dipyridamole; Humans; Kidney Failure, Chronic; Platelet Aggregation | 1988 |
12 trials available for aspirin and Diabetic Nephropathies
| Article | Year |
|---|---|
Lack of effect of aspirin in primary CV prevention in type 2 diabetic patients with nephropathy: results from 8 years follow-up of NID-2 study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Eval | 2015 |
Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] tri
Topics: Aspirin; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel; Diabetic Nephropathies; Drug | 2009 |
Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Creatinine; Diabetes Mellit | 2011 |
Assessment of the Siksika chronic disease nephropathy-prevention clinic.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Bl | 2013 |
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
Topics: Adult; Aged; Alanine Transaminase; Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Chronic Disea | 2005 |
A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Celecoxib; Creatinine; Cross-Over Studies; | 2007 |
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis Obliterans; Aspirin; Ch | 2008 |
Glucose-induced changes in renal haemodynamics in proteinuric type 1 (insulin-dependent) diabetic patients: inhibition by acetylsalicilic acid infusion.
Topics: Adult; Analysis of Variance; Aspirin; Biopsy; Blood Proteins; Diabetes Mellitus, Type 1; Diabetic Ne | 1993 |
Effects of aspirin or basic amino acids on collagen cross-links and complications in NIDDM.
Topics: Analysis of Variance; Arginine; Aspirin; Biopsy; Blood Glucose; Collagen; Cross-Linking Reagents; Cy | 1997 |
A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy.
Topics: Adult; Aged; Aspirin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipyridamole; Drug Administ | 2002 |
Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy.
Topics: Adult; Aspirin; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dipyridamole; Double-Blind Method | 1989 |
Renal scintigraphy and survival of indium-111-labelled platelets in patients with diabetic nephropathy.
Topics: Aspirin; Blood Glucose; Blood Platelets; Cell Survival; Diabetic Nephropathies; Dipyridamole; Double | 1986 |
24 other studies available for aspirin and Diabetic Nephropathies
| Article | Year |
|---|---|
Aspirin mediates protection from diabetic kidney disease by inducing ferroptosis inhibition.
Topics: Animals; Aspirin; Cell Line; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Diabetic Nephropathi | 2022 |
Aspirin mediates protection from diabetic kidney disease by inducing ferroptosis inhibition.
Topics: Animals; Aspirin; Cell Line; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Diabetic Nephropathi | 2022 |
Aspirin mediates protection from diabetic kidney disease by inducing ferroptosis inhibition.
Topics: Animals; Aspirin; Cell Line; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Diabetic Nephropathi | 2022 |
Aspirin mediates protection from diabetic kidney disease by inducing ferroptosis inhibition.
Topics: Animals; Aspirin; Cell Line; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Diabetic Nephropathi | 2022 |
Effect of diabetic kidney disease on therapeutic strategies for coronary artery disease: ten year follow-up.
Topics: Aged; Aspirin; Calcium Channel Blockers; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabeti | 2021 |
Recommendations on the Clinical Use of Compound Danshen Dripping Pills.
Topics: Angina Pectoris; Aspirin; Camphanes; Clopidogrel; Coronary Disease; Diabetes Mellitus; Diabetic Neph | 2017 |
Novel reno-protective mechanism of Aspirin involves H2AK119 monoubiquitination and Set7 in preventing type 1 diabetic nephropathy.
Topics: Animals; Aspirin; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies | 2018 |
Adverse Effect of Antithrombotic Medications on Bleeding Events and Comparison of Antithrombotic Agents in Hemodialysis Patients.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Diabetic Nephropathies; Drug Monitoring; Female; Fibrinolyti | 2019 |
Platelet Microparticles Mediate Glomerular Endothelial Injury in Early Diabetic Nephropathy.
Topics: Animals; Aspirin; Blood Platelets; Cell-Derived Microparticles; Cells, Cultured; Chemokines, CXC; Di | 2018 |
Sex-specific-differences in cardiometabolic risk in type 1 diabetes: a cross-sectional study.
Topics: Adult; Aspirin; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Complicat | 2013 |
Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2010 |
Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Diabe | 2010 |
Minocycline with aspirin: an approach to attenuate diabetic nephropathy in rats.
Topics: Animals; Aspirin; Cyclooxygenase Inhibitors; Diabetic Nephropathies; Male; Matrix Metalloproteinase | 2011 |
Roles of connective tissue growth factor and prostanoids in early streptozotocin-induced diabetic rat kidney: the effect of aspirin treatment.
Topics: Animals; Aspirin; Blotting, Northern; Cells, Cultured; Connective Tissue Growth Factor; Cyclooxygena | 2003 |
The assessment and management of albuminuria in primary care.
Topics: Aged; Albuminuria; Aspirin; Blood Glucose; Cardiovascular Diseases; Chronic Disease; Diabetes Mellit | 2008 |
Control of cardiovascular risk factors and use of aspirin in diabetic patients remain elusive.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Albuminuria; Aspirin; Blood Pressure; Chol | 2008 |
Comparative therapeutic benefit of indomethacin, hydrochlorothiazide, and acetyl-salicylic acid in a patient with nephrogenic diabetes insipidus.
Topics: Adolescent; Aspirin; Diabetes Insipidus; Diabetic Nephropathies; Dinoprost; Dinoprostone; Diuresis; | 1984 |
[Optic neuropathy in type-1 diabetes and acetylsalicylic acid-refractory thrombocyte activation].
Topics: Adult; Aspirin; Chronic Disease; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diabetic Neuropa | 1993 |
Our experience with pancreatic graft extraperitoneal placement.
Topics: Adult; Anticoagulants; Aspirin; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Drug Therapy, Com | 1997 |
Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist.
Topics: Animals; Aspirin; Autocrine Communication; Cells, Cultured; Cinnamates; Cyclooxygenase Inhibitors; D | 2002 |
Altered platelet function in diabetes mellitus.
Topics: Adenosine Diphosphate; Adult; Arachidonic Acids; Aspirin; Blood Platelets; Collagen; Cyclooxygenase | 1976 |
Anti-platelet therapy in diabetic and non-diabetic progressive renal failure.
Topics: Aspirin; Blood Pressure; Creatinine; Diabetic Nephropathies; Dipyridamole; Docosahexaenoic Acids; Dr | 1992 |
[Enzymuria and kidney diseases in childhood].
Topics: Acetylglucosaminidase; Adolescent; Aminopeptidases; Anti-Bacterial Agents; Aspirin; CD13 Antigens; C | 1986 |
Platelet-inhibitor treatment of diabetic nephropathy: a 10-year prospective study.
Topics: Adult; Aspirin; Blood Platelets; Cell Survival; Creatinine; Diabetic Nephropathies; Dipyridamole; Dr | 1988 |
Effect of aspirin on experimental diabetic nephropathy.
Topics: Animals; Aspirin; Basement Membrane; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Di | 1987 |
A kinetic evaluation of hemostasis in renal disease.
Topics: Aspirin; Blood Coagulation; Complement System Proteins; Diabetic Nephropathies; Dipyridamole; Fibrin | 1974 |
Increased platelet aggregation in diabetes mellitus.
Topics: Adenosine Diphosphate; Aspirin; Blood Chemical Analysis; Blood Proteins; Creatinine; Diabetes Mellit | 1972 |